HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Scadding, J. W Search for Related Content PubMed Articles by Scadding, J. W

The James Lind Alliance: an opportunity for neurologists in therapeutic research?

Consultant Neurologist, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; jwscadding@hotmail.com

The first 150 words of the full text of this article appear below.

The James Lind Alliance (JLA), launched just over a year ago, is named after the Scottish naval surgeon who conducted a randomised trial in scurvy, showing the superiority of citrus fruit over other treatments. The core aim of the JLA, which is a UK based organisation, is the proper involvement of patients, working together with clinicians (and not just doctors but nurses, therapists, and others), to identify important treatment uncertainties and to plan shared priorities in research (http://www.lindalliance.org).¹ It was formed to address a number of shortcomings and problems in current therapeutic research.

There are mismatches between what researchers are researching and unanswered questions asked by patients and clinicians

Firstly, there are mismatches between what researchers are researching and unanswered questions asked by patients and clinicians; linked with this, there are mismatches between treatment outcomes studied by researchers and those regarded as important by patients. Doctors’ and patients’ . . . [Full text of this article]